hotspot -WSS

hotspot

author：knowledge 2025-09-03 11:52:11 - browse：3

Light micrograph of a fatty liver — Large vacuoles of triglyceride fat, accumulated inside liver cells. Adobe

SAN DIEGO — An experimental obesity drug from Eli Lilly significantly reduced liver fat in a small analysis, supporting further studies of the treatment against nonalcoholic fatty liver disease, an increasingly common condition that lacks approved treatments.

Among 98 patients with nonalcoholic fatty liver disease, those on the highest dose tested of the drug, retatrutide, experienced an 86% decrease in liver fat over 48 weeks, with most of the reduction occurring early on in treatment, according to data presented here at the American Diabetes Association conference Monday.

Additionally, 93% of people on the highest dose achieved resolution of fatty liver disease, defined as having 5% or less liver fat.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： Addiction doctors spar with methadone clinics over legislation

WSS

Lab trade group sues FDA to halt regulation of lab

Readout Newsletter: Biotech news, Wall Street disappointment, Lilly's drug delays

Lawsuit highlights wrinkle for disputes over surprise medical bills

Average age of first period drops to 11.9 years, study shows

Akili, maker of video game for ADHD, to be acquired for 34 million

Scientists successfully use ultrasound imaging to map brain activity

hotspot

hotspot

explore

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Merck to buy EyeBio, maker of eye drug, as it grows pipeline

New air purifier tech could be key to improving indoor air quality

Adam's Biotech Scorecard: Do Sarepta's exon

DIEP, the 'gold standard' of breast reconstruction, is under threat

Startling documents reveal new facets of Sacklers' opioid empire

At least 13 dead in Texas as scorching temps continue

Merck to buy EyeBio, maker of eye drug, as it grows pipeline

Moonlake's readout produced a cash windfall. Risks remain

Gene therapies for deafness raise the question: Do deaf people want a 'cure'?

Wikipedia

Startling documents reveal new facets of Sacklers' opioid empire

2023 Nobel Prize in Medicine goes to Karikó and Weissman

Experts study whether long Covid risk adds up with each reinfection

Congress extends some pandemic preparedness programs

Stigma and the return of syphilis

Readout Newsletter: Insmed, Asahi Kasei, Agios, Royalty Pharma

hotspot

hotspot

explore

leisure time